Category Archives: Europe

BBC Takes Aim at GSK Corruption

GlaxoSmithKline’s legal wrangle concerning corrupt practices in Poland was one target of a pharma expose by the BBC’s flagship current affairs show Panorama this week. The program featured an interview with a former GSK sales rep based in Lodz, who said doctors were paid to promote GSK’s asthma drug Seretide. It was “a simple equation”, […]
Also posted in compliance, Corporate Responsibility, Events, Global | Tagged , , , , , | Leave a comment

Biopharmaceuticals: Approvals Rate Best in Five Years

Overall, last year can be considered quite a successful one in terms of new product approvals. Nineteen products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union. These approval numbers are above average compared to the previous five years, which recorded a mean approval rate of 13 products. The […]
Also posted in Biotech, Global, Guest Blog, Regulatory | Tagged , , | Leave a comment

European Regulator’s Last Ditch Attempt at Transparency

By Peter O’ Donnell. The European Medicines Agency is determined to minimize opposition to its next moves on releasing clinical trial data. It announced last week yet another consultation on its plans to publish the results of trials — a policy it initially aimed at introducing from the beginning of this year. The latest twist […]
Also posted in Global, Op-Ed, Regulatory | Tagged , , , , | Leave a comment

After Delays, Project DataSphere Rolls Out

An industry and academic data-sharing project went live on Tuesday, nearly a year after the platform was expected to launch. Visitors to the site – no credentials needed – can register and access de-identified clinical data from the comparator arms of nine oncology trials, with more to come. Project DataSphere, the newest data transparency and […]
Also posted in Biotech, Corporate Responsibility, FDA, Global, IP, leadership, Legal, R&D, Strategy, Technology | Tagged , , , , , , , , , | Leave a comment

Pricing and Reimbursement in Europe: Where Does Innovation Fit?

By Leela Barham. It was recently said, in reference to the UK’s Value-Based Assessment(VBA) program, that innovation had not been “tried and tested in the pricing context”, which explains the loss of the “innovation” criteria from the proposals formerly known as Value-Based Pricing (VBP). This prompted me to think about just how has innovation been […]
Also posted in Global, Guest Blog, pricing, R&D | Tagged , , , , , | Leave a comment
  • Categories

  • Meta